Hepcidin in chronic kidney disease anemia

• Type: Another Publication in an International Scientific Journal
• Date: 2019

Authors

Alice Santos Silva (Author) FFUP; Ribeiro, S (Author) Other; Reis, F (Author) Other; Belo, L (Author) FFUP

Journal

Title: Vitamins and Hormones

Vol. 120

Pages: 243-264

ISSN: 0083-6729

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 16 Citations

Scopus - 19 Citations

Other information

Authenticus ID: P-00R-HKA

DOI: 10.1016/bs.vh.2019.01.012

Abstract (EN): Chronic kidney disease (CKD) is associated with several complications that worsen with progression of disease; anemia, disturbances in iron metabolism and inflammation are common features. Inflammatory response starts early, releasing pro-inflammatory cytokines, acute phase reactants and hepcidin. Hepcidin production is modulated by several factors, as hypoxia/anemia, erythropoietin and erythropoiesis products, transferrin saturation (TSAT) and liver iron levels, which are altered in CKD. Treatment of CKD anemia is based on pharmaceutical intervention, with erythropoietic stimulating agents and/or iron supplementation; however, in spite of the erythropoietic benefits, this therapy, on a regular basis, involves risks, namely iron overload. To overcome these risks, some therapeutic approaches are under study to target CKD anemia. Considering the actual alerts about risk of iron overload in dialysis patients, inhibition of hepcidin, the central key player in iron homeostasis, could be a pivotal strategy in the management of CKD anemia.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 22